Compounds > n-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide
Page last updated: 2024-12-09

n-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide: inhibits dihydroorotate dehydrogenase from P. falciparum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID799096
CHEMBL ID217893
SCHEMBL ID18120561
MeSH IDM0520957

Synonyms (17)

Synonym
OPREA1_049304
OPREA1_295970
asinex compound no. 6
benzamide compound 3
n-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide
bdbm14711
STK020274
CHEMBL217893
AKOS003270080
331846-06-1
SCHEMBL18120561
DTXSID50355395
d59 ,
Z30181603
Q27459083
EN300-22650372
PD186834
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)IC50 (µMol)170.96320.00050.742710.0000AID1797377; AID275414
Dihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)Ki42.94330.01200.50372.7000AID1797270; AID275414
Dihydroorotate dehydrogenase (quinone), mitochondrialPlasmodium falciparum 3D7Ki32.21500.03000.03000.0300AID1797270
Dihydroorotate dehydrogenase Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)0.23000.23002.64439.4800AID275413
Dihydroorotate dehydrogenase Plasmodium falciparum (malaria parasite P. falciparum)Ki0.03000.03000.03000.0300AID275413
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
UDP biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
'de novo' UMP biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
pyrimidine ribonucleotide biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
'de novo' pyrimidine nucleobase biosynthetic processDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
dihydroorotase activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
protein bindingDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
dihydroorotate dehydrogenase (quinone) activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
dihydroorotate dehydrogenase activityDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleoplasmDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrionDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrial inner membraneDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
cytosolDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
mitochondrial inner membraneDihydroorotate dehydrogenase (quinone), mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID275413Inhibition of recombinant Plasmodium falciparum DHODH2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase.
AID275415Selectivity for Plasmodium falciparum recombinant DHODH over human recombinant DHODH2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase.
AID275418Inhibition of Plasmodium falciparum DHODH F188A mutant2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase.
AID275414Inhibition of human recombinant DHODH2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase.
AID1338076Antiparasitic activity against Plasmodium falciparum NF54 infected in human erythrocytes by [3H]-hypoxanthine incorporation assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
AID1338075Selectivity ratio of IC50 for human DHODH to IC50 for Plasmodium falciparum DHODH2017European journal of medicinal chemistry, Jan-05, Volume: 125Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
AID1338074Inhibition of Plasmodium falciparum DHODH2017European journal of medicinal chemistry, Jan-05, Volume: 125Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
AID1797270DHODH Inhibition Assay from Article 10.1021/jm060687j: \\Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase.\\2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase.
AID1797377DHODH Inhibition Assay from Article 10.1074/jbc.M501100200: \\High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.\\2005The Journal of biological chemistry, Jun-10, Volume: 280, Issue:23
High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.63 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
5,6-dihydroorotate
4,5-dihydroorotic acid: RN given refers to cpd without isomeric designation; structure. dihydroorotic acid : A pyrimidinemonocarboxylic acid that results from the base-catalysed cyclisation of N(alpha)-carbethoxyasparagine.		2.0310monocarboxylic acid;
N-acylurea;
pyrimidinemonocarboxylic acid;
secondary amide
2,3-dimethoxy-5-methyl-6-decyl-1,4-benzoquinone
2,3-dimethoxy-5-methyl-6-decyl-1,4-benzoquinone: ubiquinol analog. 6-decylubiquinone : A member of the class of 1,4-benzoquinones that is 2,3-dimethoxybenzoquinone which has been substituted at positions 5 and 6 by decyl and methyl groups.		2.03101,4-benzoquinonescofactor
dsm 74
[no description available]		3.2510
teriflunomide
[no description available]		2.4420(trifluoromethyl)benzenes;
aromatic amide;
enamide;
enol;
nitrile;
secondary carboxamide		drug metabolite;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
hepatotoxic agent;
non-steroidal anti-inflammatory drug;
tyrosine kinase inhibitor
flavin mononucleotide
Flavin Mononucleotide: A coenzyme for a number of oxidative enzymes including NADH DEHYDROGENASE. It is the principal form in which RIBOFLAVIN is found in cells and tissues.		2.0410
ConditionIndicatedRelationship StrengthStudiesTrials